Qing-Sheng Mi

Dr. Qing-Sheng Mi is a Professor and Henry W. Lim Endowed Chair of Dermatology Research, as well as Vice Chair for Research in the Department of Dermatology. He is the Founder and Director of The Center for Cutaneous Biology and Immunology and Director of The Immunology Research Program at Henry Ford Cancer Institute, Henry Ford Health System (HFH). Additionally, he has affiliations with the Department of Medicine at Michigan State University and serves as Co-Director of the Immunology Focus Group at Wayne State University (WSU) School of Medicine/HFH. He is also adjunct professor, the Department of Chemistry, Microbiology, and Immunology and Dept of Oncology at WSU.

Dr. Mi earned his MD from The First Shandong Medical University (formerly Taishan Medical College) in China in 1985 and his Ph.D. in Immunodermatology from China Medical University in 1992. He completed his dermatology training in China, where he was a professor and vice chair in the Department of Dermatology at First Shandong Medical University before relocating to the U.S. in 1995. Following extensive training in basic immunology and autoimmune diseases at the National Institute on Aging/NIH and Robarts Research Institute in Canada, Dr. Mi established his research lab in the Department of Pathology and the Section of Dermatology/Department of Medicine at the Medical College of Georgia in 2003, where he was promoted to tenured Associate Professor in 2008. He joined HFH in 2008 from the Medical College of Georgia.

Dr. Mi has authored over 150 publications in leading journals and serves as an editor, associate editor, and on editorial boards of more than 10 journals. His contributions have been recognized with a Presidential Citation Award from the American Academy of Dermatology and the Outstanding Scientist Award by the Henry Ford Medical Group.

His current research encompasses both basic (using mouse models) and translational (human disease) studies, employing multi-omics approaches such as scRNA-Seq, scATAC-Seq, sc-spatial transcriptomics, CyTOF, proteomics, and whole genome sequencing. These efforts aim to explore genetic and epigenetic immune regulations in cancer and skin inflammatory diseases, including drug discovery and immunotherapy. His research is currently supported by four NIH grants and one DOD grant:
1.	Using Integrative Functional Genomics to Uncover Immunopathogenesis of Skin Inflammatory Disease - Hidradenitis Suppurativa (Funded by two NIH/NAIMS RO1s and one R21 grants)
2.	HDAC3 as a Potential Therapeutic Target for Langerhans Histiocytosis (Funded by DOD)
3.	VPS72 as an epigenetic regulator to control Treg cell stability and adaptation to tumor microenvironment (NIH/NCI RO1)